The application is supported by data from the phase 2b/3 HPTN 083 and HPTN 084 trials, which evaluated the efficacy and safety of Apretude for HIV PrEP. The Food and Drug Administration (FDA) has ...

In a move to increase access to HIV-prevention treatment, the U.S. Food and Drug Administration on Monday approved the use of Apretude – the first injectable pre-exposure prophylaxis treatment aimed ...

As GSK’s ViiV Healthcare looks to widen the reach of its HIV franchise, Médecins Sans Frontières (MSF) has been working to secure access to the company's long-acting HIV prevention drug, Apretude, for ...

In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, seven participants contracted the virus despite receiving their ...

Karla Torres, senior medical liaison for ViiV Healthcare, said her company’s mission is to “Leave No One Behind.” ViiV is the only drug company whose only focus is on HIV medication, she said, ...

Add Yahoo as a preferred source to see more of our stories on Google. food and drug administration fda alzheimer's disease dementia aducanumab drug treatment fast track approval The Food and Drug ...

After making history with the first complete long-acting regimen for the treatment of HIV, GlaxoSmithKline’s ViiV Healthcare has now made a component of that therapy into a preventative option, ...

A new injectable treatment for HIV pre-exposure prevention, or PrEP, has been approved by the Federal Drug Administration. The drug, Apretude, is approved for at-risk adults and adolescents who weigh ...

A new study aims to help healthcare providers more effectively implement Apretude, a medication used for HIV prevention. A new study explores how healthcare providers can effectively implement ...

The Food and Drug Administration (FDA) has approved the first injectable treatment for HIV pre-exposure prophylaxis, providing another option to help individuals at-risk avoid sexually transmitted HIV ...